Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians

被引:8
作者
Macdonald, Courtney [1 ,2 ]
Saunders, Christobel M. [3 ]
Keogh, Louise A. [4 ]
Hunter, Morgan [5 ]
Mazza, Danielle [6 ]
Mclachlan, Sue-Anne [7 ,8 ]
Jones, Sandra C. [9 ]
Nesci, Stephanie [1 ]
Friedlander, Michael L. [10 ,11 ]
Hopper, John L. [12 ]
Emery, Jon D. [13 ,14 ,15 ]
Hickey, Martha [16 ,17 ]
Milne, Roger L. [12 ,18 ,19 ]
Phillips, Kelly-Anne [1 ,2 ,12 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[3] Univ Western Australia, Crawley, WA, Australia
[4] Univ Melbourne, Ctr Hlth Equ, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[6] Monash Univ, Dept Gen Practice, Melbourne, Vic, Australia
[7] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia
[8] St Vincents Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Australian Catholic Univ, ACU Engagement, Melbourne, Vic, Australia
[10] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia
[11] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
[12] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia
[13] Univ Melbourne, Victorian Comprehens Canc Ctr, Dept Gen Practice, Melbourne, Vic, Australia
[14] Univ Melbourne, Victorian Comprehens Canc Ctr, Ctr Canc Res, Melbourne, Vic, Australia
[15] Univ Western Australia, Sch Primary Aboriginal & Rural Hlth Care, Perth, WA, Australia
[16] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[17] Royal Womens Hosp, Melbourne, Vic, Australia
[18] Canc Council Victoria, Canc Epidemiol Div, Melbourne, Vic, Australia
[19] Monash Univ, Precis Med, Sch Clin Sci, Monash Hlth, Melbourne, Vic, Australia
[20] Peter MacCallum Canc Ctr, Res Dept, Melbourne, Vic, Australia
基金
欧盟地平线“2020”; 英国医学研究理事会;
关键词
RISK-ASSESSMENT; ATYPICAL HYPERPLASIA; FOLLOW-UP; TAMOXIFEN; PREVENTION; RALOXIFENE; MANAGEMENT;
D O I
10.1158/1940-6207.CAPR-20-0369
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Guidelines endorse the use of chemoprevention for breast cancer risk reduction. This study examined the barriers and facilitators to chemoprevention use for Australian women at increased risk of breast cancer, and their clinicians. Surveys, based on the Theoretical Domains Framework, were mailed to 1,113 women at >= 16% lifetime risk of breast cancer who were enrolled in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer cohort study (kConFab), and their 524 treating clinicians. Seven hundred twenty-five women(65%) and 221 (42%) clinicians responded. Only 10 (1.4%) kConFab women had ever taken chemoprevention. Three hundred seventy-eight (52%) kConFab women, two (3%) breast surgeons, and 51 (35%) family physicians were not aware of chemoprevention. For women, the strongest barriers to chemoprevention were side effects (31%) and inadequate information (23%), which operate in the Theoretical Domains Framework domains of "beliefs about consequences" and "knowledge," respectively. Strongest facilitators related to tamoxifen's long-term efficacy (35%, "knowledge," "beliefs about consequences," and "goals" domains), staying healthy for family (13%, "social role" and "goals" domains), and abnormal breast biopsy (13%, "environmental context" domain). The strongest barrier for family physicians was insufficient knowledge (45%, "knowledge" domain) and for breast surgeons was medication side effects (40%, "beliefs about consequences" domain). The strongest facilitators for both clinician groups related to clear guidelines, strong family history, and better tools to select patients ("environmental context and resources" domain). Clinician knowledge and resources, and beliefs about the side-effect consequences of chemoprevention, are key domains that could be targeted to potentially enhance uptake. Prevention Relevance: Despite its efficacy in reducing breast cancer incidence, chemoprevention is underutilised. This survey study of Australian women and their clinicians used behavioural change theory to identify modifiable barriers to chemoprevention uptake, and to suggest interventions such as policy change, educational resources and public campaigns, that may increase awareness and use.
引用
收藏
页码:131 / 144
页数:14
相关论文
共 50 条
  • [31] Chemoprevention for Breast Cancer
    Sandhya Pruthi
    Ruth E. Heisey
    Therese B. Bevers
    Annals of Surgical Oncology, 2015, 22 : 3230 - 3235
  • [32] Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions
    Lawal, Kehinde O.
    Nilan, Luisa
    Amenta, Jacquelyn
    McGuinness, Julia E.
    Kukafka, Rita
    Crew, Katherine D.
    CANCER PREVENTION RESEARCH, 2023, 16 (12) : 661 - 667
  • [33] Breast Cancer Chemoprevention: The Saga of Underuse Continues
    Wickerham, D. Lawrence
    Vogel, Victor G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (01):
  • [34] Chemoprevention of breast cancer for mutation carriers and other high risk women
    Decensi, A.
    Puntoni, M.
    BREAST, 2009, 18 : S4 - S5
  • [35] Selecting women for breast cancer chemoprevention and what agents should be used
    J Cuzick
    Hereditary Cancer in Clinical Practice, 10 (Suppl 2)
  • [36] Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
    Vogel, Victor G.
    CURRENT DRUG TARGETS, 2011, 12 (13) : 1874 - 1887
  • [37] Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor
    Flanagan, Meghan R.
    Zabor, Emily C.
    Stempel, Michelle
    Mangino, Debra A.
    Morrow, Monica
    Pilewskie, Melissa L.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (07) : 2127 - 2135
  • [38] Breast cancer chemoprevention - a vision not yet realized
    Blaha, P.
    Dubsky, P.
    Fitzal, F.
    Bachleitner-Hofmann, T.
    Jakesz, R.
    Gnant, M.
    Steger, G.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (05) : 438 - 446
  • [39] Chemoprevention of Breast Cancer with Fenretinide
    Rosalba Torrisi
    Andrea Decensi
    Franca Formelli
    Tiziana Camerini
    Giuseppe De Palo
    Drugs, 2001, 61 : 909 - 918
  • [40] Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
    Kondo, M.
    Hoshi, S-L
    Toi, M.
    BRITISH JOURNAL OF CANCER, 2009, 100 (02) : 281 - 290